Exubera Efficacy In Type 1 Diabetes "Intensive" Control Questioned By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer/Sanofi trial shows only 23% of Type 1 diabetes patients receiving inhaled insulin achieved standard of care for glycemic control, FDA tells advisory committee in briefing materials for Sept. 8 meeting.
You may also be interested in...
Pfizer/Sanofi Exubera Effective For Both Type 1 And Type 2 Diabetes, Committee Says
Advisory committee rejects FDA contention that inhaled insulin may not have shown intensive glycemic control in Type 1 diabetes.
Pfizer/Sanofi Exubera Effective For Both Type 1 And Type 2 Diabetes, Committee Says
Advisory committee rejects FDA contention that inhaled insulin may not have shown intensive glycemic control in Type 1 diabetes.
Pfizer's Exubera Inhaled Insulin To Be Reviewed By Endocrine Committee Sept. 8
Inhalation powder will be evaluated for diabetes mellitus in adults by FDA's Endocrinologic & Metabolic Drugs Advisory Committee. Developed in conjunction with Sanofi-Aventis, Exubera would be first inhaled insulin product.